Paul Tomasic, Managing Director and Head of European Healthcare at Houlihan Lokey, sat down with Investors in Healthcare to discuss the current tailwinds in the pharmaceutical services industry and the underlying factors driving the need for an ever-greater volume and complexity of new drug development.
Read the article here.